HomeEmployersRemix Therapeutics
R

Remix Therapeutics

8 open positions
Last updated Nov 18, 2026
Remote5%
Hybrid0%
On-site95%
Salary shown84%
Avg. listing115d
This month2 new · 1 closed

Director, Companion Diagnostics

$206k–$252k/year
48
Low

Remix Therapeutics is a clinical-stage biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin. Remix's REMaster™ technology platform leverages data science, biomolecular sciences and chemistry approaches to ide

OtherExecutive
See 1 similar>
2 0 0 7d ago

Senior Director, Clinical & Commercial Supply Chain

$230k–$281k/year
48
Low

Remix Therapeutics is a clinical-stage biopharmaceutical company pioneering a new class of medicines that modulate RNA splicing to address the underlying biology of disease. Our lead program, REM-422, targets pre-mRNA splicing in oncology and represents a fundamentally differentiated approach to dru

OtherSenior
See 1 similar>
1 0 0 8d ago

Director, Commercial Project Management & Launch Excellence

$206k–$252k/year
34
Lowest

Remix Therapeutics is a clinical-stage biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin. Remix's REMaster™ technology platform leverages data science, biomolecular sciences and chemistry approaches to ide

OperationsProject ManagerExecutive
See 2 similar>
3 0 0 23d ago

Director, Clinical Pharmacology

$206k–$252k/year
34
Lowest

Remix Therapeutics is a clinical-stage biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin. Remix's REMaster™ technology platform leverages data science, biomolecular sciences and chemistry approaches to ide

OtherExecutive
See 1 similar>
2 0 0 23d ago

Senior Director, GCP Quality

$230k–$281k/year
34
Lowest

Remix Therapeutics is a clinical-stage biopharmaceutical company pioneering a new class of medicines that modulate RNA splicing to address the underlying biology of disease. Our lead program, REM-422, targets pre-mRNA splicing in oncology and represents a fundamentally differentiated approach to dru

OtherSenior
See 1 similar>
2 0 0 1mo ago

Associate Director, Clinical Data Management

23
Lowest

Remix Therapeutics is a clinical-stage biopharmaceutical company that has pioneered a new class of small molecule medicines targeting the RNA splicing machinery — correcting the disease-causing errors that drive cancers and other serious conditions at their source. REM-422 is our lead program curren

OtherData ManagementExecutive
See 2 similar>
4 0 0 1mo ago

Head of Medical Affairs

$293k–$415k/year
34
Lowest

Remix launched with a vision to transform patients’ lives through modulation of RNA processing. Our breakthrough science enables the identification of small molecules that influence the expression of disease‑driving mRNAs and proteins. We focus on diseases of high unmet medical need and are committe

OtherHealthcarePhysicianHeadExecutive
See 4 similar>
4 0 0 1mo ago

Vice President/Senior Director, Nonclinical Drug Safety & Toxicology

$293k–$358k/year
34
Lowest

Remix launched with a vision to transform patients’ lives through modulation of RNA processing. Our breakthrough science enables the identification of small molecules that influence the expression of disease‑driving mRNAs and proteins. We focus on diseases of high unmet medical need and are committe

OtherSafetyExecutive
See 2 similar>
2 0 0 2mo ago